NLS Biotech News

Biotech Business – January 13, 2026

Evaxion expands AI-Immunology platform into autoimmune diseases

Thus, Evaxion will in the future work within cancers, infectious and autoimmune diseases as its core disease areas.

Biotech Business – January 2, 2026

MSD will not exercise its option for Evaxion’s Gonorrhea vaccine candidate

Consequently, Evaxion retains global rights to EVX-B2 and will look for another potential licensing partner.
Sponsored content

CERN maximizes uptime of the world’s largest and most complex machine with HxGN EAM

With 23 member states, CERN, the European Organization for Nuclear Research, is the world’s largest research center for particle physics.

Biotech Business – December 17, 2025

Cellevate achieves ISO 9001:2015 certification

This marks a major milestone for Cellevate to becoming an industrial bioprocessing supplier, states the company.

Biotech Business – December 15, 2025

Hansa Biopharma reorganizes

Hansa Biopharma has announced a reorganization of its European and International Commercial and Medical Affairs operations, effective December 11, 2025.

Clinical trials

Clinical Trials – January 12, 2026

Elicera Therapeutics announces final data from its Phase I/IIa trial

Elicera Therapeutics has announced final data from its Phase I/IIa clinical trial evaluating the oncolytic virus ELC-100 in patients with advanced, end-stage neuroendocrine tumors who had exhausted all currently available therapeutic options and having progressing diseases.

Clinical Trials – January 9, 2026

Sobi to advance Gamifant in interferon-gamma-driven sepsis

Sobi has announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.

Clinical Trials – January 8, 2026

Herantis Pharma reports encouraging data from Phase 1b trial

Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson’s disease, states the company.

Clinical Trials – January 7, 2026

BioInvent reports promising Phase 2a study data

BioInvent International has announced encouraging interim results from its ongoing Phase 2a signal-seeking study evaluating BI-1808, a novel immuno-oncology candidate, in combination with MSD’s anti-PD-1 therapy KEYTRUDA in patients with recurrent ovarian cancer who have progressed following platinum-based therapy.

Clinical Trials – January 2, 2026

Hemab Therapeutics announces positive complete Phase 2 data

Hemab Therapeutics has announced positive results from its completed Phase 2 multiple ascending dose (MAD) portion of the CL-101 study of sutacimig for the prophylactic treatment of Glanzmann thrombasthenia (GT).

Clinical Trials – December 17, 2025

Zelluna publishes new preclinical data

Zelluna has announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances.

Clinical Trials – December 16, 2025

Affibody accelerates Phase 1 study

The Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy (RLT) candidate ABY-271 in HER2-positive metastatic breast cancer to its second part, where higher radioactivity levels will be evaluated. 

Clinical Trials – December 11, 2025

Muna Therapeutics doses first subjects in Phase 1 trial

It is a phase 1 single-ascending dose/multiple-ascending dose study of lead asset MNA-001 in healthy adult participants.

Clinical Trials – December 10, 2025

AnaCardio reports new Phase 2a results

AnaCardio has announced topline results from the Phase 2a portion of its GOAL-HF1 clinical study program evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF).

Clinical Trials – December 8, 2025

Aurealis Therapeutics announces positive Phase 2 results

The company has announced positive blinded evaluator efficacy results and completion of the Database Lock (DBL) in its DIAMEND Phase 2 clinical trial of AUP-16, the company’s lead asset for the treatment of non-healing neuro-ischemic Diabetic Foot Ulcers (DFUs).

Profiles in Biotech

Profiles in Biotech – April 23, 2024

Mia Phillipson: Pioneering immunotherapies

Despite being the co-founder of Ilya Pharma and co-director at the Science for Life Laboratory (SciLifeLab), Dr. Mia Phillipson, considers herself a scientist foremost, not an entrepreneur.

Profiles in Biotech – November 28, 2023

Kristian Tryggvason: Reshaping the cell therapy sector

The previous founder and CEO of BioLamina has gone back to business development, and with his newly founded company he aims to redefine cell therapy development even further.

Profiles in Biotech – July 28, 2021

Mathias Uhlén: Driven by curiosity and courage

Being a scientist or an entrepreneur is hard enough. Doing both at the same time sounds like an Olympic sport.

Profiles in Biotech – March 8, 2021

Sara Mangsbo – Scientist and entrepreneur

An academic and an entrepreneur, Dr. Sara Mangsbo, PhD, has found a way to integrate her skills and interests so that they complement and augment her passions.

Profiles in Biotech – January 7, 2021

Evelina Vågesjö: ”I want to see my work go beyond the lab”

What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company.

Profiles in Biotech – October 8, 2020

Robert Langer: Making a difference in medicine

Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD, turned his chemical engineering skills to medicine, becoming one of the world’s leaders in perfecting effective drug delivery systems.

Profiles in Biotech – June 13, 2018

Britt Meelby Jensen: Accelerating Danish biotech business

She has been called the Danish biotech queen and she is not afraid of responsibility in her role as CEO. On the contrary, Britt Meelby Jensen enjoys leading, setting ambitious goals and accelerating company growth.

Profiles in Biotech – October 6, 2017

Next-generation biotech entrepreneurs

For young scientists and engineers, a startup can be part of early training and education.

Profiles in Biotech – December 16, 2016

Agnete Fredriksen: “You really need to have drive to make it work”

Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula.

More biotech stories

Biotech article - January 7, 2026

The European Commission has presented its proposed Biotech Act

The Biotech Act is an initiative to strengthen Europe's competitiveness in biotechnology and drug development.

Biotech Business - January 2, 2026

Alvotech announces European launch of first-in-market biosimilar to Simponi

Alvotech has announced that launches are underway in Europe for Gobivaz (golimumab), Alvotech’s biosimilar to Simponi (golimumab), also known as AVT05 (prefilled syringe and autoinjector).

Biotech Business - December 9, 2025

Leqembi included in China’s commercial insurance innovative drug list

BioArctic’s partner Eisai has announced that Leqembi (lecanemab), has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.

Biotech Business - December 2, 2025

NextCell collaborates with OptiCell 

The collaboration concerns the handling, freezing, storage, and transport of cell products used for research and development.

Biotech Business - November 28, 2025

FDA grants Medivir’s MIV-711 Orphan Drug Designation

Medivir's selective cathepsin K inhibitor, MIV-711, has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Osteogenesis Imperfecta (OI).

Biotech Business - November 24, 2025

Alvotech receives European approval of a biosimilar to Prolia and Xgeva

“This milestone reflects not only the dedication and expertise of our teams, but also the strong partnerships we have built to bring affordable medicines to patients across Europe,” says Robert Wessman, Chairman and Chief Executive Officer of Alvotech.
Follow NLS news
Follow us on XFollow us on LinkedIn

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.